June 11, 2024
OncoBone attended the European Calcified Tissue Society (ECTS) Annual Meeting on May 25-28 in Marseille, France. The event covered main areas in basic and clinical research and provided opportunities for scientists to network and share their research. Interesting research areas for OncoBone included osteoimmunology, basic research sessions discussing interactions between bone and immune cells, and […]
September 14, 2023
OncoBone has partnered with a small-molecule CDMO service provider to expand its drug development service offering. Below you can find more information about the services, and you can request additional information by reaching info@oncobone.com. Scope of the CDMO offering The partner CDMO of OncoBone has been a trusted provider since 2001. They operate in 3 […]
September 6, 2023
OncoBone is a distributor of small-animal DXA iNSiGHT in Europe. Basics of DXA technology and its use in bone and metabolic diseases DXA (Dual-energy X-ray Absorptiometry) is a measurement technology based on variable absorption of high and low energy X-rays by different body components, allowing fast and reliable analysis of bone, soft and fat tissues. […]
July 12, 2023
OncoBone recently published a new review article in the Journal ‘Frontiers in Immunology’. The publication ‘Insights into immuno-oncology drug development landscape with focus on bone metastasis’ was a collaboration with Bioseeker Group and the publication was made possible by using their 1stOncology database for searching novel immunotherapies with effects on bone metastases. The publication summarizes […]
May 16, 2023
At the end of 2022 OncoBone received funding from Centre for Economic Development, Transport and the Environment (ELY Centre) for developing a Virtual CRO concept as a new business model. The project was co-funded by European Regional Development Fund of the European Union. This blog post summarized the outcome of the project and the Virtual […]
April 6, 2023
OncoBone has partnered with a global leading CRDMO service provider to complement its drug development service offering. Below you can find more information about the service, and you can request additional information by reaching info@oncobone.com. What is a CRDMO? CRDMO stands for Contract Research Development and Manufacturing Organization. The partner CRDMO of OncoBone has special […]
March 28, 2023
OncoBone is a distributor of small-animal DXA iNSiGHT in Europe. DXA technology: Gold Standard for body composition analysis DXA (Dual-energy X-ray Absorptiometry) is a measurement technology that is based on variable absorption of X-rays by different body components. DXA uses high and low energy X-ray photons that are differentially absorbed by different tissue types, including […]
February 7, 2023
OncoBone was contacted by Mesothelioma Hope to discuss the possibility to help raise awareness of mesothelioma, a rare cancer mainly caused by exposure to asbestos. As oncology is one of OncoBone’s areas of expertise, agreed to write a blog post to highlight the issue for our network. To our surprise, during the writing process we […]
June 10, 2022
European Calcified Tissue Society (ECTS) Annual Meeting was held in Helsinki, Finland on May 6-10, 2022. In the history of the society, this was the third time that the annual meeting was held in our home country, after 2000 in Tampere and 1980 in Helsinki. The annual meeting gathered basic and clinical researchers to meet […]
June 2, 2022
This year’s American Association of Cancer Research (AACR) Annual meeting was held in New Orleans, USA from April 8 to 13. The event was the first Annual Meeting held in-person after 2019. Due to governmental and travel restriction, there was also a possibility to attend online and listen to streamed content via a virtual platform. […]
If you are interested to learn more,
see our services or contact us directly.
